Mohammad Alrawashdeh1,2, Michael Klompas1,3, Simeon Kimmel3, Marc R Larochelle3, Runa H Gokhale4, Raymund B Dantes5,6, Brooke Hoots5,7, Kelly M Hatfield4, Sujan C Reddy4, Anthony E Fiore4, Edward J Septimus1,8, Sameer S Kadri8, Russell Poland9, Kenneth Sands1,10, Chanu Rhee1,3. 1. Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Health Care Institute, Boston, MA. 2. Jordan University of Science and Technology, Ar-Ramtha, Jordan. 3. Department of Medicine, Brigham and Women's Hospital, Boston, MA. 4. Department of Medicine, Boston University School of Medicine, Boston, MA. 5. Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA. 6. Department of Medicine, Emory University School of Medicine, Atlanta, GA. 7. Division of Overdose Prevention, Centers for Disease Control and Prevention, Atlanta, GA. 8. Texas A&M College of Medicine, Houston, TX. 9. Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD. 10. Clinical Operations Group, HCA Healthcare, Nashville, TN.
Abstract
OBJECTIVES: Widespread use and misuse of prescription and illicit opioids have exposed millions to health risks including serious infectious complications. Little is known, however, about the association between opioid use and sepsis. DESIGN: Retrospective cohort study. SETTING: About 373 U.S. hospitals. PATIENTS: Adults hospitalized between January 2009 and September 2015. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Sepsis was identified by clinical indicators of concurrent infection and organ dysfunction. Opioid-related hospitalizations were identified by the International Classification of Diseases, 9th Revision, Clinical Modification codes and/or inpatient orders for buprenorphine. Clinical characteristics and outcomes were compared by sepsis and opioid-related hospitalization status. The association between opioid-related hospitalization and all-cause, in-hospital mortality in patients with sepsis was assessed using mixed-effects logistic models to adjust for baseline characteristics and severity of illness.The cohort included 6,715,286 hospitalizations; 375,479 (5.6%) had sepsis, 130,399 (1.9%) had opioid-related hospitalizations, and 8,764 (0.1%) had both. Compared with sepsis patients without opioid-related hospitalizations (n = 366,715), sepsis patients with opioid-related hospitalizations (n = 8,764) were younger (mean 52.3 vs 66.9 yr) and healthier (mean Elixhauser score 5.4 vs 10.5), had more bloodstream infections from Gram-positive and fungal pathogens (68.9% vs 47.0% and 10.6% vs 6.4%, respectively), and had lower in-hospital mortality rates (10.6% vs 16.2%; adjusted odds ratio, 0.73; 95% CI, 0.60-0.79; p < 0.001 for all comparisons). Of 1,803 patients with opioid-related hospitalizations who died in-hospital, 928 (51.5%) had sepsis. Opioid-related hospitalizations accounted for 1.5% of all sepsis-associated deaths, including 5.7% of sepsis deaths among patients less than 50 years old. From 2009 to 2015, the proportion of sepsis hospitalizations that were opioid-related increased by 77% (95% CI, 40.7-123.5%). CONCLUSIONS: Sepsis is an important cause of morbidity and mortality in patients with opioid-related hospitalizations, and opioid-related hospitalizations contribute disproportionately to sepsis-associated deaths among younger patients. In addition to ongoing efforts to combat the opioid crisis, public health agencies should focus on raising awareness about sepsis among patients who use opioids and their providers.
OBJECTIVES: Widespread use and misuse of prescription and illicit opioids have exposed millions to health risks including serious infectious complications. Little is known, however, about the association between opioid use and sepsis. DESIGN: Retrospective cohort study. SETTING: About 373 U.S. hospitals. PATIENTS: Adults hospitalized between January 2009 and September 2015. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Sepsis was identified by clinical indicators of concurrent infection and organ dysfunction. Opioid-related hospitalizations were identified by the International Classification of Diseases, 9th Revision, Clinical Modification codes and/or inpatient orders for buprenorphine. Clinical characteristics and outcomes were compared by sepsis and opioid-related hospitalization status. The association between opioid-related hospitalization and all-cause, in-hospital mortality in patients with sepsis was assessed using mixed-effects logistic models to adjust for baseline characteristics and severity of illness.The cohort included 6,715,286 hospitalizations; 375,479 (5.6%) had sepsis, 130,399 (1.9%) had opioid-related hospitalizations, and 8,764 (0.1%) had both. Compared with sepsis patients without opioid-related hospitalizations (n = 366,715), sepsis patients with opioid-related hospitalizations (n = 8,764) were younger (mean 52.3 vs 66.9 yr) and healthier (mean Elixhauser score 5.4 vs 10.5), had more bloodstream infections from Gram-positive and fungal pathogens (68.9% vs 47.0% and 10.6% vs 6.4%, respectively), and had lower in-hospital mortality rates (10.6% vs 16.2%; adjusted odds ratio, 0.73; 95% CI, 0.60-0.79; p < 0.001 for all comparisons). Of 1,803 patients with opioid-related hospitalizations who died in-hospital, 928 (51.5%) had sepsis. Opioid-related hospitalizations accounted for 1.5% of all sepsis-associated deaths, including 5.7% of sepsis deaths among patients less than 50 years old. From 2009 to 2015, the proportion of sepsis hospitalizations that were opioid-related increased by 77% (95% CI, 40.7-123.5%). CONCLUSIONS: Sepsis is an important cause of morbidity and mortality in patients with opioid-related hospitalizations, and opioid-related hospitalizations contribute disproportionately to sepsis-associated deaths among younger patients. In addition to ongoing efforts to combat the opioid crisis, public health agencies should focus on raising awareness about sepsis among patients who use opioids and their providers.
Authors: Beth Hume; Barbara Gabella; Jeanne Hathaway; Scott Proescholdbell; Cristy Sneddon; Elizabeth Brutsch; Riley Hedin; Christopher J Drucker Journal: Public Health Rep Date: 2017-06-20 Impact factor: 2.792
Authors: Laura R Marks; Satish Munigala; David K Warren; Stephen Y Liang; Evan S Schwarz; Michael J Durkin Journal: Clin Infect Dis Date: 2019-05-17 Impact factor: 9.079
Authors: Michael Wolfson; Susan E Wallace; Nicholas Masca; Geoff Rowe; Nuala A Sheehan; Vincent Ferretti; Philippe LaFlamme; Martin D Tobin; John Macleod; Julian Little; Isabel Fortier; Bartha M Knoppers; Paul R Burton Journal: Int J Epidemiol Date: 2010-07-14 Impact factor: 7.196
Authors: Elana S Rosenthal; Adolf W Karchmer; Jesse Theisen-Toupal; Roger Araujo Castillo; Chris F Rowley Journal: Am J Med Date: 2015-11-18 Impact factor: 4.965
Authors: Chanu Rhee; Michael R Filbin; Anthony F Massaro; Amy L Bulger; Donna McEachern; Kathleen A Tobin; Barrett T Kitch; Bert Thurlo-Walsh; Aran Kadar; Alexandra Koffman; Anupam Pande; Yasir Hamad; David K Warren; Travis M Jones; Cara O'Brien; Deverick J Anderson; Rui Wang; Michael Klompas Journal: Crit Care Med Date: 2018-10 Impact factor: 7.598
Authors: Svetlana Puzhko; Mark J Eisenberg; Kristian B Filion; Sarah B Windle; Andréa Hébert-Losier; Genevieve Gore; Elena Paraskevopoulos; Marc O Martel; Irina Kudrina Journal: Front Public Health Date: 2022-02-22